1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: Will PEGASUS data make AstraZeneca's Brilinta fly?

Physician Views: Will PEGASUS data make AstraZeneca's Brilinta fly?

  • March 2015
  • ID: 3509575
  • Format: PDF
  • By Firstword Pharma


Despite the publication of full data from AstraZeneca's PEGASUS-TIMI 54 study this weekend, their remains mixed views as to whether trial results will drive a significant increase in the use of the platelet aggregation inhibitor Brilinta.

The PEGASUS study has been designed to evaluate whether the continued treatment of acute coronary syndrome (ACS) patients with the combination of Brilinta and aspirin reduces the risk of subsequent heart attacks. It is standard practice to treat ACS patients with a combination of aspirin and an adenosine diphosphate (ADP) receptor inhibitor such as Brilinta, Sanofi's Plavix or Eli Lilly's Effient for a 12-month period, while PEGASUS is assessing whether extension of this treatment over subsequent years is effective. AstraZeneca has suggested a positive result could effectively double the commercial opportunity of Brilinta versus its current label.

As announced in January, top-line data from PEGASUS demonstrated a statistically significant reduction in major cardiovascular events (a composite primary endpoint comprising cardiovascular death, myocardial infarction or stroke). Full data released this weekend demonstrated that versus placebo, the combination of Brilinta and aspirin delivered a relative risk reduction of 15 percent to 16 percent (depending on Brilinta dose), or an absolute level of reduction of 1.2 percent.

The primary safety endpoint of PEGASUS was major bleeding and unsurprisingly the presence of two antiplatelet agents in the Brilinta arm resulted in a higher rate versus placebo (2.5 percent versus 1.0 percent). The rate of intracranial/fatal bleeding was consistent across both arms.

While some analysts remain bullish that full data from PEGASUS is supportive of AstraZeneca's peak revenue forecasts ($3.5 billion versus 2014 sales of $476 million), others are sceptical that the new results will have any significant impact on increased uptake of Brilinta. One potential barrier to uptake is design of the PEGASUS study, and specifically the choice to compare Brilinta against placebo rather than Sanofi's Plavix.

A sub-analysis of the 2007 CHARISMA study (which influenced the design of PEGASUS) demonstrated that the combination of Plavix and aspirin delivered similar results to the extended use of Brilinta and aspirin. As a result, analysts at Bernstein estimate that around 20 percent of eligible Brilinta patients in the US are already treated with this combination, with Plavix now available generically at a significantly lower cost. Is it plausible that positive data from PEGASUS could actually stimulate further penetration of this much cheaper combination (on an off-label basis) at the expense of Brilinta market share gain?

Another factor to consider, as noted in an editorial published in the NEJM alongside publication of the PEGASUS study, is whether the balance of higher efficacy, but increased bleeding, is "close to an even proposition." Noting that treating 10 000 patients with low-dose Brilinta over the course of one year "would prevent approximately 42 primary endpoint events and produce approximately 31 major bleeding events," the editorial argues that PEGASUS results may "prompt speculation as to whether dual platelet inhibition with high-potency agents is approaching the point of diminishing returns."

Speaking on a conference call held by AstraZeneca on Monday, Marc Sebatine – lead investigator of the PEGASUS study - noted that Plavix use in this setting is evidence that physicians need something more effective than aspirin monotherapy, and Brilinta can fill this gap (as the only drug which has data to support this indication). Sebatine also argued that major bleeding events are reversible, thus he disagrees with the issue of "diminishing returns" raised in the NEJM editorial.

To better understand the impact of the PEGASUS data, FirstWord is this week polling US and EU5-based cardiologists. Specifically we are asking them…

How impressive do they think the PEGASUS data are?
Whether they think the PEGASUS data will have an indirectly positive impact on usage of generic clopidogrel in this indication?
Whether they agree with statements made in the NEJM editorial (the net clinical benefit is "close to an even proposition" and that data could prompt speculation as to whether "dual platelet inhibition with high-potency agents is approaching the point of diminishing returns")?
How they expect their usage of Brilinta to evolve in this indication based on the PEGASUS data?
Whether they think that Brilinta will only be used in this indication in highly selected patients with lower risk of bleeding complications and particularly high cardiovascular risk, rather than the broader ACS population?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2020

Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020

Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2020Summaryclinical trial report, “Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2020" provides an overview of Irritable Bowel ...

Cancer Pain - Pipeline Review, H2 2019

Cancer Pain - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Cancer Pain - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2019, provides an overview of the Cancer Pain (Central Nervous ...

Plague - Pipeline Review, H1 2020

Plague - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Plague - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H1 2020, provides an overview of the Plague (Infectious Disease) pipeline ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on